We’ve all been waiting for cancer vaccines to become a thing. It’s been a very long wait. But I can tell you now, with some assurance, that this is right around the corner. There are new vaccines being built for cancer, and more are being developed as we speak.
We all thought this would happen many years (decades?) ago. But the dedicated scientists who work in this industry know how difficult it really is to build a cancer vaccine that works. Stay tuned!
Our intrepid science master Clark Jones has an exciting story on one of these trials. The aim is to create a unique vaccine for each patient by analyzing their tumor DNA to identify specific mutations that can be targeted by the immune system.
In Clark’s piece, the first man to participate in the trial, Elliot Pfebve, expressed his optimism about the potential of personalized cancer vaccines, stating, “It may help thousands, if not millions of people, so they can have hope, and may not experience all I have gone through.” Elliot previously received surgical tumor removal and chemotherapy before enrolling in the trial.
And finally, there is our writer Preetam Kaushik’s piece on PD-1 Immune checkpoint inhibitors and cancer. It is a remarkable treatment that is still being honed for the treatment of a variety of cancers.
PD-1 and PD-L1 checkpoint inhibitors, as they are called, are advanced immunotherapy drugs that show a lot of promise in helping us fight cancer using the body’s defense mechanisms. As of 2023, these drugs have been approved for the treatment of at least nine different cancers.
What’s New This Week:
When Will We See More New FDA-Approved Cancer Vaccines In Our Neighborhood Cancer Clinics?
First Patients to Receive Personalized Cancer Vaccines
PD-1 Immune Checkpoint Inhibitors and Cancer
